A Risk-Benefit Assessment of Sildenafil in the Treatment of Erectile Dysfunction

ISSN： 0114-5916

Source： Drug Safety, Vol.24, Iss.4, 2001-01, pp. : 255-265

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Risk-Benefit Assessment of Alendronate in the Treatment of Involutional Osteoporosis

By Devogelaer J-P.

Drug Safety, Vol. 19, Iss. 2, 1998-08 ,pp. : 141-154

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Injections of Hyaluronan and its Derivatives in the Treatment of Osteoarthritis of the Knee

By Adams M.E.

Drug Safety, Vol. 23, Iss. 2, 2000-08 ,pp. : 115-130

Adis International

Access to resources Recommend Favorite

Interferon- Treatment of Patients with Hepatitis C: The Role of a Comprehensive Risk-Benefit Assessment

By Muhamad Aly Rifai Loftis Jennifer M. Hauser Peter

CNS Drugs, Vol. 19, Iss. 8, 2005-01 ,pp. : 719-721

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Risperidone for the Treatment of Behavioural and Psychological Symptoms in Dementia

By Zaudig M.

Drug Safety, Vol. 23, Iss. 3, 2000-09 ,pp. : 183-195

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Treatment with Finasteride in Benign Prostatic Hyperplasia

By Ekman P.

Drug Safety, Vol. 18, Iss. 3, 1998-03 ,pp. : 161-170

Adis International

Access to resources Recommend Favorite